Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04298138 · ClinicalTrials.gov registry record · Phase 1
Dengue 3 Human Infection Model (DENV-3)
A Phase 1 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04298138: Completed Phase 1 study, sponsored by State University of New York - Upstate Medical University.
NCT04298138 is a Phase 1 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04298138, a Phase 1 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit an uncomplicated dengue-like illness.
Primary Outcome
Total number of all abnormal labs
Interventions
- BIOLOGICAL Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2021-12-14 |
| Phase | Phase 1 |
What the finished NCT04298138 record still lists
NCT04298138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) is the first listed.
NCT04298138 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04298138 about?
NCT04298138 is a clinical study titled "Dengue 3 Human Infection Model (DENV-3)". To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit...
What is the current status of trial NCT04298138?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-08-03. Estimated completion is 2021-12-14.
What interventions are being tested in trial NCT04298138?
The interventions under investigation include: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04298138?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04298138's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI